Dr Reddy’s Laboratories launched Bosutinib tablets, a generic equivalent of Bosulif, in the US, expanding its oncology portfolio.
Hyderabad-based Dr. Reddy’s collaborated with MSN Laboratories on the product. Dr. Reddy’s holds the exclusive marketing rights for the product in the US. MSN is responsible for the development and manufacturing of the product. Bosutinib was a first-to-file product and is eligible for 180-days of generic drug exclusivity for this strength, in the US.
“This launch highlights our commitment to leading with timely market entry for high-priority therapies, while broadening access for both patients and healthcare providers. With this launch, we remain focused on strengthening our oncology portfolio and partnering across the healthcare system to ensure that critical treatments are both accessible and affordable.”
Bharat Reddy, Executive Director, MSN Laboratories said: “The successful development and commercialisation of Bosutinib Tablets demonstrates MSN’s strong scientific, regulatory, and manufacturing capabilities in complex oncology products.”
The Bosulif brand of Wyeth LLC had US sales of approximately $253.8 million for the latest 12-month period ended April 2026, according to IQVIA National Sales Perspectives data.
Published on June 13, 2026
